Glaucoma & Retinopathies 2010

The global market for ophthalmic pharmaceuticals is a profitable and prestigious segment, set to reach total sales of $32.36bn by 2025 (IMS Health). Glaucoma and retinopathies remain the largest and fastest-growing therapeutic categories, and significant unmet needs. Neuroprotection is now the recognised Holy Grail for glaucoma, along with new technologies to boost patient compliance. For retinopathies, inhibiting geographic atrophy, oedema and neovascularisation remain significant challenges. For both, improved screening methods are driving clinical end-point validation.

Bringing you the latest in basic, pre-clinical, translational and clinical research, we showcase the latest in a field rich in opportunities. Updates from outstanding speakers cover:
Full market analysis including prospects for pipeline therapies
New insights into retinal ganglion cell pathology, degeneration and apoptosis
Innovative in vivo techniques to increase the spatial resolution of retinal imaging for the optic nerve and retina
Increasing the effectiveness of neuroprotective agents beyond monotherapy
Defining and validating clinical measures of neuroprotection
Sustained release intraocular devices to boost patient compliance
Gene, encapsulated-cell and cell replacement therapies for retinopathies
Developments in anti VEGF treatments for wet AMD
RNAi therapeutics for wet AMD and diabetic macular oedema
Antibody therapies for age-related macular degeneration and diabetic retinopathy